List view / Grid view
19 December 2013 | By AstraZeneca
Global agreement strengthens AstraZeneca’s commitment to diabetes, a key growth platform in a core strategic area for the company...
19 December 2013 | By Daiichi Sankyo Company
Daiichi Sankyo is seeking approval in Japan for edoxaban in new indications for non-valvular atrial fibrillation (AF) and symptomatic venous thromboembolism...
18 December 2013 | By Merck
“Collaborations like this are central to Merck’s strategy to evaluate the potential of MK-3475 for the treatment of cancer..."
17 December 2013 | By Amgen
Study meets co-primary endpoints of LDL cholesterol reduction...
17 December 2013 | By Abbott
This highly advanced diagnostic tool measures the internal optics and surface of the eye more precisely than conventional methods...
17 December 2013 | By
AstraZeneca is aware of reports that an 505(b)(2) NDA esomeprazole strontium product has been launched in the US by Hanmi Pharmaceutical and affiliates...
17 December 2013 | By GlaxoSmithKline
GSK sets out plans to evolve the way it sells and markets its products to healthcare professionals...
17 December 2013 | By Biogen Idec
Biogen Idec opts-in to commercialization opportunity with joint venture partner...
16 December 2013 | By GlaxoSmithKline
GSK intends to keep the Company publicly-listed...
16 December 2013 | By Boehringer Ingelheim,
"These data are encouraging as they demonstrate that HCV genotype-1 infected patients irrespective of the presence of the common HCV Q80K variant..."
13 December 2013 | By Daiichi Sankyo
Daiichi Sankyo Espha launched two new generic drugs with two new active ingredients and two generic drugs with an additional standard...
13 December 2013 | By AstraZeneca
Lesinurad is an investigational agent being studied as a selective uric acid re-absorption inhibitor that inhibits the URAT1 transporter...
12 December 2013 | By IFPAC
IFPAC is the essential meeting place for the latest developments in Process Analytical Technology...
12 December 2013 | By AstraZeneca
Advisory Committee recommends metreleptin for the treatment of paediatric and adult patients with generalised lipodystrophy...
12 December 2013 | By Merck
GRASTEK is the proposed trade name for the company’s investigational sublingual tablet for the treatment of Timothy grass induced allergic rhinitis...
